As part of Q2 Solutions end-to-end biomarker capabilities, we harness our bioanalytical capabilities to aid in the development and implementation of biomarkers.
Q2 Solutions is one of the few bioanalytical laboratories successfully employing immunoprecipitation techniques and multidimensional liquid chromatography (LC) for biomarker quantitation. Q2 Solutions offers a wide range of tailored and integrated liquid chromatography mass spectrometry services to support biomarker testing and quantitation, including LC/MS bioanalysis, LC/MS/MS analysis, hybrid LC-MS assays, small molecule LC/MS, and large molecule bioanalysis. Our team has experience and knowledge in developing and validating biomarker assays for definitive quantitation of endogenous analytes, including proteins, peptides, lipids, neurotransmitters, steroids, amino acids, and other biomarker analytes. The development of these assays is followed by method validation or qualification, and sample analysis consistent with global regulatory requirements and governed by SOPs.
We have a broad set of capabilities to support biomarker identification and analysis.
Q2 Solutions is your partner of choice for any development program which requires identifying or measuring biomarkers. Through our experience and expertise we can help you understand how these biomarkers can deliver actionable medical insights for better health. Since 2015 Q2 Solutions has validated >450 new assays including over 250 biomarker assays each year.
Alzheimer’s disease (AD) remains an area of severe unmet need and decades of research have yet to deliver validated diagnostics to evaluate disease progression. In 2021, only one marketed drug aimed...
In today's evolving, dynamic clinical development environment, central laboratories must adapt to meet the growing demand for early biomarker evaluation before advancement into clinical trials....
Alan Wookey, Companion Diagnostics and Oncology Scientific Advisor at Q² Solutions along with Kristina McGuire, Sr. Director & Head of CDx and Lab operations at Regeneron and Shirin Hasan, Associate,...